Phase II trial of preoperative carboplatin (carbo)/pemetrexed (pem) in patients (pts) with select stage IB-IIIA nonsquamous non-small cell lung cancer (NS-NSCLC)
| Autor: | Donald C. Townsend, David Michael Waterhouse, F. Anthony Greco, R. Brian Mitchell, Victor M. Priego, Fred J. Kudrik, Howard A. Burris, Michael McCleod, David R. Spigel, John D. Hainsworth, Ralph V. Boccia, Kent C. Shih |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Cisplatin Cancer Research Chemotherapy medicine.medical_specialty business.industry medicine.medical_treatment Standard treatment Vinorelbine medicine.disease Carboplatin Surgery chemistry.chemical_compound Pemetrexed chemistry Internal medicine Medicine Stage (cooking) business Lung cancer medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 32:e18510-e18510 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2014.32.15_suppl.e18510 |
| Popis: | e18510 Background: Adjuvant platinum-based chemotherapy is standard treatment (tx) in select early stage NSCLC. Adjuvant cisplatin/pem was safe, less toxic, and easier to deliver than vinorelbine/cisplatin in a randomized phase II trial (Kreuter Ann Onc 2013). Potential benefits of preoperative tx are earlier tx of micrometastatic NSCLC and better tx tolerance. This is a phase II trial of preoperative carbo/pem in select stage IB-IIIA NS-NSCLC. Methods: Eligible pts had potentially resectable T2 N0 (>4cm), T1-2 N1-N2 (1 N2 zone, biopsy proven), and T3-T4 N0-1 (not superior sulcus) NS-NSCLC (TNM 6th Ed.). Pts received carbo AUC 6 and pem 500mg/m2 IV D 1 q21 D x 4, followed by imaging, surgery, and routine follow-up (f/u). The primary aim was to assess 3-yr overall survival (OS); and secondary aims to assess response, progression-free survival (PFS), and safety. Results: 46 pts were enrolled: stage IB (11%), II (37%), and IIIA (52%); median age 65 yrs (42-82); 61% female; and 93% smokers. Median f/u: 16 mos... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|